Bortezomib and daratumumab in refractory autoimmune hemolytic anemia

达拉图穆马 自身免疫性溶血性贫血 硼替佐米 医学 耐火材料(行星科学) 免疫学 肿瘤科 溶血性贫血 内科学 贫血 多发性骨髓瘤 生物 天体生物学
作者
John McGlothlin,Jithma P. Abeykoon,Eyad Al‐Hattab,Aneel A. Ashrani,Michelle A. Elliott,C. Christopher Hook,Animesh Pardanani,Rajiv K. Pruthi,Meera Sridharan,Alexandra P. Wolanskyj,Rachelle Rouse,Ronald S. Go
出处
期刊:American Journal of Hematology [Wiley]
卷期号:98 (10): E263-E265 被引量:7
标识
DOI:10.1002/ajh.27025
摘要

Autoimmune hemolytic anemia (AIHA) mostly includes cold agglutin disease (CAD), warm AIHA (wAIHA), and mixed AIHA. It arises from autoantibody destruction of erythrocytes (RBCs) with or without complement fixation but emerging evidence has demonstrated more diverse pathophysiology involving imbalance of T-helper 1/2 cytokines, increased activity of cytotoxic CD8+ T lymphocytes, and bone marrow compensation.1 This newer understanding has helped explain the intractable nature of AIHA refractory to standard immunosuppressive or B-cell-directed agents.2 One mechanism for treatment failure of AIHA involves an inability to deplete long-lived bone marrow and splenic plasma cells responsible for chronic autoantibody production in classic immunosuppressant and CD20 therapy. As a result, therapy targeting short- and long-lived plasma cells has been proposed as a method to treat the origin of these antibodies. There is currently a growing body of evidence of the efficacy of plasma cell-directed therapies in refractory AIHA. Two agents that have notably demonstrated clinical efficacy for refractory AIHA are bortezomib and daratumumab. Daratumumab—a CD38 monoclonal antibody—has shown potential in refractory AIHA through its mechanism of targeting long-lived plasma cells responsible for autoantibody production involved in AIHA. Daratumumab currently has documented potential benefit in as many as 12 select case reports for refractory AIHA but the majority of these studies are limited to pediatric patients or hematopoietic stem cell transplant recipients.3 A second treatment under investigation for refractory AIHA is the proteasome inhibitor bortezomib which induces apoptosis in both clonal and reactive antibody-producing cells. Bortezomib has demonstrated efficacy in one prospective, open-label study for CAD in addition to multiple case reports.4 We aim to demonstrate clinical safety and efficacy of plasma cell-directed therapies daratumumab and bortezomib for refractory AIHA through a single-institution retrospective review. After obtaining IRB approval, we retrospectively reviewed the medical records of patients with AIHA seen at our institution between 2012 and 2022. Eligible patients included adults with AIHA who were treated with either bortezomib or daratumumab or both. Additional inclusion criteria were all of the following: (A) age ≥ 18 years; (B) diagnosis of WAIHA (direct antiglobulin test [DAT] IgG+ ± C3+), CAD (DAT IgG-/C3+ with cold agglutinin titer >1:64), or mixed disease; (C) active disease (hemoglobin [Hb] <10 g/dL plus biochemical evidence of hemolysis); and (D) relapsed from or refractory to other treatments. Responses were based on the international consensus criteria and classified as complete (CR; normal Hb or Hb ≥12 g/dL, with normalized laboratory markers of hemolysis), partial response (PR; Hb >10 but <12 g/dL or at least an increase by >2 g/dL, with or without biochemical resolution of hemolysis) or no response (neither complete nor PR). Adverse events were measured using Common Terminology Criteria for Adverse Events v5.0. The primary objective of the study was to describe the efficacy and duration of responses. Eight patients met our study criteria. The clinical features and treatment outcomes are summarized in Table 1. Over half of the patients (5/8; 63%) were males. The median age at the time of treatment was 61 years (range, 34–78) and the median duration of follow-up was 10.4 months (range, 4–42 months). Six patients had WAIHA and 2 had CAD (2). Three patients received bortezomib alone, 2 daratumumab alone, and 3 bortezomib + daratumumab. Seven of the eight patients had secondary hematologic diseases including low-grade B cell lymphoma, monoclonal gammopathy of undetermined significance (MGUS), chronic myelomonocytic leukemia (CMML), idiopathic thrombocytopenic purpura (ITP) and therapy-related acute myeloid leukemia (AML). A majority of patients (6/8; 67%) had received at least three lines of treatment prior to initiating either daratumumab or bortezomib. Overall response rate was 88% (7/8), with 63% (5/8) and 25% (2/8) achieving complete response (CR) and PR, respectively. The median length of treatment for patients who demonstrated CR was 2 months. Five (62%) patients were transfusion dependent. Median time to treatment was 2.1 months (range, 1–5 months). Additionally, the mediation duration of response was 24.5 months (range, 15–42 months). The only patient who did not respond to treatment (patient 5) had WAIHA and Waldenström macroglobulinemia and received the combination of bortezomib and daratumumab. This patient subsequently died from sepsis and pulmonary embolism unrelated to treatment. Of the remaining 7 patients who responded to treatment, all are alive at the time of this report. Four of the 8 patients tolerated their treatments with no adverse events. One patient developed grade 1 injection site reaction and one patient developed grade 1 dizziness. One patient developed grade 2 nausea and vomiting and another developed grade 3 atrial fibrillation. While refractory AIHA remains an intractable condition with low response rates to first- and second-line therapies, newer pharmacologic interventions targeting alternative pathways such as complement inhibition, B-cell therapy, and autoantibody production have shown early clinical promise. Specifically, plasma cell-directed therapies have generated recent interest for refractory AIHA with emerging evidence suggesting promising safety and efficacy profiles in this setting. We demonstrate the safety and efficacy of plasma-cell-directed therapies daratumumab and bortezomib for refractory AIHA. Our study shows a high rate of clinical response with over 50% of patients achieving a CR. Additionally, the median length of treatment to response was relatively short at <2 months. The duration of response was also long lasting with an average of >2 years and the longest duration was >3 years. The relative safety of these therapies is also demonstrated by the lack of side effects in half of the patients with only one patient having a grade 3 adverse event. Despite a growing body of evidence for bortezomib and daratumumab in refractory AIHA, the overall duration of response in these studies has been small and is demonstrated predominately in patients who are status-post HSCT.5 Here we demonstrate the use of these therapies in patients who have not had HSCT. The combination of clinical response with long-lasting duration and a strong safety profile supports the promising nature of bortezomib and daratumumab in refractory AIHA. With emerging evidence that CD20-negative plasma cells might propagate the immune response responsible for intractable AIHA, these findings could help guide clinical management for refractory AIHA moving forward. One limitation of the study is its retrospective nature. While there is one prospective study assessing the safety and efficacy for bortezomib in the setting of CAD, prospective studies will be helpful in validating plasma-cell therapies for future clinical use.4 Although this study has a relatively small dataset that limits its generalizability, it is also one of the few case series that adds to the growing body of evidence for both daratumumab and bortezomib safety and efficacy in refractory AIHA. This study demonstrates the efficacy of plasma cell-directed therapies, bortezomib, and daratumumab, in the treatment of refractory AIHA patients. Additionally, our results highlight that these agents are generally well tolerated and can provide long-lasting remissions. Future prospective studies will hopefully continue to corroborate these findings and allow for more widespread use of impactful therapy in refractory AIHA. This project has no funding source and has no disclosure. Rajiv K. Pruthi MD: Bayer Healthcare AG: Honoraria, Membership on an entity's Board of Directors or advisory committees; HEMA Biologics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Instrumentation Laboratory: Honoraria, Membership on an entity's Board of Directors or advisory committees; Merck: Consultancy; Genentech Inc: Honoraria, Membership on an entity's Board of Directors or advisory committees; CSL Behring: Honoraria, Membership on an entity's Board of Directors or advisory committees. Meera Sridharan MD: Alexion Pharmaceuticals: Consultancy. The remaining do not have any financial conflict of interest to disclose regarding this work. This study was approved by the Mayo Clinic Institutional Review Board which was deemed to be no more than minimal risk and informed consent for patients was waived. Permission was granted to reproduce material from other sources. This study does not qualify as a clinical trial. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Maestro_S的应助被MUMU采纳,获得10
刚刚
清脆的秋寒完成签到,获得积分10
刚刚
1秒前
东风的应助被寻寻123采纳,获得20
2秒前
casino的应助被chms采纳,获得10
4秒前
所所的应助被LUXURY采纳,获得10
4秒前
梦梦发布了新的文献求助30
4秒前
4秒前
文艺宛筠完成签到,获得积分20
5秒前
XM完成签到,获得积分10
5秒前
5秒前
5秒前
5秒前
6秒前
6秒前
6秒前
6秒前
kiwi完成签到,获得积分10
6秒前
温柔的契完成签到,获得积分10
8秒前
沫燃完成签到 ,获得积分10
8秒前
孤独碧空完成签到,获得积分10
9秒前
Jasmine发布了新的文献求助10
10秒前
Poem发布了新的文献求助10
10秒前
燕麦片完成签到 ,获得积分10
10秒前
单薄的小鸽子完成签到 ,获得积分10
10秒前
lucia发布了新的文献求助10
10秒前
如意幻枫完成签到,获得积分10
10秒前
11秒前
11秒前
shd发布了新的文献求助10
11秒前
xyb发布了新的文献求助10
11秒前
玩家666发布了新的文献求助10
12秒前
ke发布了新的文献求助10
12秒前
恍若隔世发布了新的文献求助20
12秒前
zhikaiyici发布了新的文献求助30
12秒前
lkh发布了新的文献求助10
13秒前
桑桑完成签到,获得积分10
13秒前
秋风的应助被Felix采纳,获得10
14秒前
科研通AI6.2的应助被胡萝卜卜采纳,获得10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193653
求助须知:如何正确求助?哪些是违规求助? 9579816
关于积分的说明 21867585
捐赠科研通 7793288
什么是DOI,文献DOI怎么找? 3437343
关于科研通互助平台的介绍 2560779
邀请新用户注册赠送积分活动 2484193